124. 皮質下梗塞と白質脳症を伴う常染色体優性脳動脈症 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Clinical trials / Disease details


臨床試験数 : 12 薬物数 : 14 - (DrugBank : 5) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 11

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCTs051220072
09/08/202209/08/2022Effect of Lomerizine Hydrochloride on Preventing Recurrence of Cerebral Ischemic Events in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and LeukoencephalopathyEffect of Lomerizine Hydrochloride on Preventing Recurrence of Cerebral Ischemic Events in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy - LOMCAD Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
CADASIL;D046589
Lomerizine hydrochloride (MIGSYS tablets 5 mg, 1 tablet twice daily) will be administered continuously for 24 months as the study drug.Mizuno ToshikiNULLRecruiting>= 20age old<= 70age oldBoth20N/AJapan